Pharmaceutical Technology on MSN10h
Orphelia explores avenues for liquid neuroblastoma med after EU CHMP rejection
Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
Hosted on MSN12d
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Morningstar13d
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP ...
Novartis announces CHMP of EMA adopted positive opinion for Fabhalta
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...
Crain's Chicago Business12d
Europe poised to OK another use for AbbVie's Rinvoq
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
Valneva reports positive CHMP opinion for adolescent label extension for Ixchiq
Valneva (VALN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Morningstar13d
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...
BioArctic: The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...